正在布局抗腫瘤藥產品線的Lilly繼續(xù)發(fā)力
繼收購Armo BioSciences之后
今日又宣布收購AurKa Pharma
1.1億美元首付款
外加4.65億美元的里程碑款項
以及一定的銷售額分成
AurKa Pharma
2016年成立于加拿大蒙特利爾
TVM Capital Life Science Venture Capital第十二個投資項目
成立之初
正是旨在開發(fā)Lilly旗下抗腫瘤活性化合物
也是此次看中的為Aurora激酶抑制劑AK-01
目前處于臨床I期研究中
Aurora激酶主要參與調節(jié)中心體和微管的功能
以保證染色體的精確分離和胞質的有效分離
通常都在G2-M期達到高峰
調節(jié)著細胞周期中G2-M轉換
是調節(jié)M期進展的關鍵因子
Aurora激酶由3個亞群組組成
Aurora-A、Aurora-B和Aurora-C
此時的過表達則導致遺傳的不穩(wěn)定性
造成細胞多倍體誘發(fā)惡性腫瘤
AurKa旗下的AK-01對Aurora-A有高度選擇性
臨床I期試驗也證明了潛在的臨床收益
后續(xù)臨床將繼續(xù)評估臨床收益與風險的結果
Senior vice president of corporate business development at LillyThe acquisition of AurKa Pharma supports Lilly's external innovation strategy, in which we seek to partner with leading life science venture capital firms in order to identify, support and access promising innovation in areas of unmet medical need. We are excited with the value TVM created for this compound through its early-Phase studies, and we look forward to more opportunities in the future.
Managing Partner at TVM Capital Life ScienceThrough the unique healthcare venture capital model pioneered by TVM Capital Life Science, companies such as AurKa have been established to more quickly and efficiently bring promising compounds to clinical proof-of-concept. We are pleased that the scientific advances made by AurKa could contribute to the development of AK-01 and hopefully help deliver a potential new medicine for cancer patients.
